naive group. Icariin and Compact disc11 were utilized to examine the mobile area of pNFB, CXCL1, and CXCR2. The consequences of CXCR2 and NFB antagonists and CXCL1 neutralizing antibody on pain hypersensitivity were evaluated by behavioral testing. Outcomes BCP induced cortical bone tissue damage and consistent mechanised allodynia and elevated the appearance of pNFB, CXCL1, and CXCR2 in vlPAG. The induced phosphorylation of NFB was co-localized with NeuN and GFAP, however, not with Compact disc11. Micro-injection of BAY11-7082 attenuated BCP and decreased CXCL1 upsurge in the spinal-cord. The expression degree of CXCL1 in vlPAG demonstrated co-localization with GFAP, however, not with NeuN and CD11. Micro-administration of CXCL1 neutralizing antibody from 6 to 9?times after inoculation attenuated mechanical allodynia. Furthermore, vlPAG application of CXCL1 elicited pain hypersensitivity in normal rats. Interestingly, CXCR2 was upregulated Icariin in vlPAG neurons (not with CD11 and GFAP) after BCP. CXCR2 antagonist SB225002 completely blocked the CXCL1-induced mechanical allodynia and attenuated BCP-induced pain hypersensitivity. Conclusion The NFB-dependent CXCL1-CXCR2 signaling cascade played a role in glial-neuron interactions and in descending facilitation of BCP. Electronic supplementary material The online version of this article (10.1186/s12974-018-1391-2) contains supplementary material, which is available to authorized users. Keywords: CXCL1, CXCR2, Periaqueductal gray, Glia-neuron interaction, Bone cancer pain, Icariin NFB Background Bone cancer pain (BCP) is usually a severe and chronic pain that has a unfavorable impact on the quality of life of cancer patients. Developments in the mechanisms and pharmacotherapy of BCP have achieved limited success, and commonly-used analgesics have resulted in little or no response. Therefore, novel and more efficacious therapies are urgently needed for improving the patients quality of life. Recent studies have exhibited that hyperalgesia in animal models with prolonged pain is closely associated with the activation of top-down modulatory circuits including descending facilitation or descending inhibition [1, 2]. The ventrolateral periaqueductal gray (vlPAG) is a substantial component of the descending pain modulatory network and exerts inhibitory or excitatory control on pain transmission via the rostral ventromedial medulla (RVM), which in turn projects to the spinal dorsal horn [3C5]. The increased net descending pain modulatory drive prospects to an amplification of the pain [2, Rabbit Polyclonal to OR9A2 6C8]. However, the cellular and molecular mechanisms underlying the injury-induced synaptic plasticity in the descending facilitation of vlPAG circuitry are poorly understood. Accumulating evidence demonstrated an important role of neuroimmune interactions in chronic pain [9]. Glial hyperactivity and its associated chemokines contribute to prolonged pain in the spinal dorsal horn [9, 10]. Recent studies around the models of chronic pain have exhibited glial activation in PAG [11, 12] associated with changes in cytokines/chemokines [13]. Moreover, the chemokine CXCL1, also known as keratinocyte-derived chemokines (KC) or growth-related oncogene (GRO), is usually a member of CXC family and has been demonstrated to play a critical role in the induction and maintenance of inflammatory pain [14], neuropathic pain [15, 16], and BCP [17] facilitation via its favored receptor, CXCR2 [18, 19]. These data suggested that CXCL1 and CXCR2 are involved in astroglial-neuronal conversation in the spinal cord under chronic pain conditions. Comparable processes that are involved in the alteration of descending pain modulation may occur in vlPAG. Nuclear factor kappa B (NFB) is usually a transcription factor that transduces extracellular signals to impact gene expression [17]. NFB is usually involved in TNF-induced CXCL1 expression in main astrocytes [20]. Moreover, emerging evidences have indicated that this activation of NFB following inflammatory pain, neuropathic pain, Icariin and BCP is related to the generation of chronic pain [21C23]. Studies have reported that NFB mediates CXCL1 expression in the spinal astrocytes and contributes to BCP [17]. Whether NFB mediates CXCL1 expression in vlPAG astrocytes and contributes to the descending facilitation of BCP needs further investigation. Hence, the present study was aimed to investigate the hypothesis that CXCL1/CXCR2 signaling in vlPAG is usually involved in descending the pain.